(4S,5R)-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-methylphenyl]methyl]-4-methyl-5-[3-methyl-5-(trifluoromethyl)phenyl]-1,3-oxazolidin-2-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4S,5R)-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-methylphenyl]methyl]-4-methyl-5-[3-methyl-5-(trifluoromethyl)phenyl]-1,3-oxazolidin-2-one
• 化学式: C₃₀H₃₁F₄NO₃
• 分子量: 529.6
• InChiKey: HCURRBZEHCJRSO-VKGTZQKMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF
  申请人：Humljan Jan

  公开号：US20140135368A1

  公开（公告）日：2014-05-15

  The present invention relates to the field of organic chemistry, more specifically to the synthesis of intermediate compounds which can be used in the synthesis of pharmaceutically active agents such as anacetrapib or derivatives thereof.

  本发明涉及有机化学领域，更具体地涉及合成中间化合物，这些化合物可用于合成药物活性剂，如阿那普利或其衍生物。
• Inhibitors of Cholesterol Ester Transfer Protein
  申请人：Concert Pharmaceuticals, Inc.

  公开号：US20150011595A1

  公开（公告）日：2015-01-08

  The invention relates to novel oxazolidinones their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering cholesterol ester transfer protein inhibitors.

  本发明涉及新型噁唑烷酮及其衍生物，药学上可接受的盐、溶剂合物和水合物。本发明还提供了包含本发明化合物的组合物，并将这种组合物用于治疗通过给予胆固醇酯转移蛋白抑制剂有益治疗的疾病和条件的方法。
• CETP INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140221383A1

  公开（公告）日：2014-08-07

  Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R 2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH 2 —.

  具有I式结构的化合物，包括化合物的药物可接受盐，是CETP抑制剂，可用于提高HDL胆固醇，降低LDL胆固醇，并用于治疗或预防动脉粥样硬化：在I式化合物中，B或R2是具有正交芳基，杂环，苯并杂环或苯并环烷基取代基的苯基，而5元环的另一个位置具有直接连接到环或通过-CH2-连接到环的芳基，杂环，环烷基，苯并杂环或苯并环烷基取代基。
• CETP Inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20160075724A1

  公开（公告）日：2016-03-17

  Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R 2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH 2 —.

  具有I式结构的化合物，包括这些化合物的药学上可接受的盐，是CETP抑制剂，可用于提高HDL-胆固醇，降低LDL-胆固醇，以及用于治疗或预防动脉粥样硬化。在I式化合物中，B或R2是具有正交芳基，杂环，苯并杂环或苯并环烷基取代基的苯基，而5元环的另一个位置具有直接连接到环或通过—CH2—连接到环的芳基，杂环，环烷基，苯并杂环或苯并环烷基取代基。
• US9212118B2
  申请人：——

  公开号：US9212118B2

  公开（公告）日：2015-12-15